MAY 28, 2018 09:45 AM PDT

Wilms Tumor Clinical Trial Combined Chemo Treatment Results in Reduced Use of Radiotherapy for Lung Metastases

 

About Wilms Tumor

Wilms tumor, also known as nephroblastoma, begins in the kidneys.  It is the most common form of cancer of the kidneys diagnosed in children.  Its name originates from the first doctor, a German man named Max Wilms, who characterized the disease in 1899.  Wilms tumors can become quite large very quickly and are often mid-late stage cancer at diagnosis in these kids, however, many are found before metastasis has occurred.  It is estimated that there are 500 new cases of Wilms tumor in the United States annually, with these representing approximately 5% of all childhood cancers.  Average age of diagnosis is 3-4 years and is uncommon after age 6; adult diagnoses are very rare.   There are two types of Wilms tumor categorized as “favorable histology” and “unfavorable histology or anaplastic”.  The greater the anaplasia (or differences in cancer cell morphology), the harder it is to cure.

Risk Factors for Wilms Tumor

Risk factors for Wilms tumor include race, family history, and heritable genetic factors.  Studies have found that Wilms tumor risk is marginally higher in African-American children and is lowest in Asian-American children.  If there is a family history of Wilms tumor, 1-2% of diagnoses can be attributed to that; researchers have found that the familial link is not usually a parent with Wilms tumor.  This risk group is also more likely to have bilateral tumors, whereas 95% of Wilms tumors are unilateral.  There are also some known birth defects that are clustered with Wilms tumor including aniridia (loss of iris presence), genitourinary tract abnormalities (defects in structure or function), and mental retardation.  There is a syndrome called WAGR that represents this cluster of symptoms; each symptom first letter is represented in the syndrome name.  There is an identified tumor suppressor gene, WT1, which if mutated, can result in Denys-Drash Syndrome or Frasier Syndrome.  Both patients diagnosed with these syndromes are at higher risk of developing Wilms tumor.  Another gene associated with Wilms, WT2 on chromosome 11, can become mutated and result in Beckwith-Wiedemann Syndrome.  These children tend to be large for their age and according to the American Cancer Society, have about a 5% risk of Wilms tumor development.  There are yet other syndromes with lesser risks including Perlman, Sotos, Simpson-Colabi-Behmel, Bloom, Li-Fraumeni, and Trisomy 18.

Newest Treatment Findings in Wilms Tumor

A clinical trial study recently published in the Journal of Clinical Oncology, sponsored by the Children’s Oncology Group, has been completed after many years of follow up and evaluation of children with Wilms tumor.  Their Phase III trial goal was to determine how well combination chemotherapy with or without radiation therapy works in young patients with stage III or stage IV favorable histology Wilms tumor and lung metastases.  The group determined to use DD4A which is a chemotherapy regimen consisting of Vincristine, Dactinomycin, and Doxorubicin.  Among the 292 assessable patients of the study, 159 had incomplete response to DD4A alone but had response with the combination of DD4A with 4 cycles of cyclophosphamide/etoposide and lung radiation therapy.  The remaining 133 patients with complete lung nodule response (CR) achieved this with DD4A chemotherapy without lung radiation therapy. 

The promise of this finding is the reduction of use of lung radiation therapy in these young children.  Lung radiation therapy can cause long term damage or late effects because of the cellular damage done as a result of treatment.  These late effects may not manifest themselves until years after therapy has commenced but include breast cancer, heart problems, pulmonary toxicity, and decreased lung function due to early onset pulmonary fibrosis, pneumonitis, obstructive lung diseases, and decreased lung volume.  Additional studies to follow up these findings can further develop treatment regimens that increase event free survival rates and decrease therapy use.  Advanced molecular testing and sequencing may be future options to build profiles to help direct patients and providers to treatment plans that successfully eradicate with minimal collateral damage.  That has and will always been the goal of providers and researchers.  

Sources: ClinicalTrials.Gov, Journal of Clinical Oncology, American Cancer Society, Chest,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUN 05, 2018
Cancer
JUN 05, 2018
Clinical Trial Evaluates Precision Medicine Approaches for Common and Rare Cancers
The NCI-MATCH Phase II Clinical Trial is evaluating results of cancer treatments administered based on genetic profiles determined through molecular diagnostic testing....
JUN 07, 2018
Clinical & Molecular DX
JUN 07, 2018
Digital Screening Vital for Detecting Breast Cancer
A combination of two digital techniques could be the best way to diagnose breast cancer. In a new study, scientists show how combining a technique called t...
JUN 26, 2018
Cancer
JUN 26, 2018
Genomic Markers Identified for Infant Soft Tissue Tumors
A new article from Nature Communications published on June 18, 2018 now outlines a newly discovered connection between infant soft tissue tumors and the mutations involving EGFR and BRAF gene...
AUG 13, 2018
Videos
AUG 13, 2018
What does sunscreen look like with a UV camera?
  Have you ever wondered if there’s really a difference between SPF 30 and SPF 50? You’re not the only one. YouTuber Physics Girl set out...
SEP 12, 2018
Microbiology
SEP 12, 2018
Researchers ID a Link Between a Bacterial Strain and Gastric Cancer
Helicobacter pylori is a bacterium that causes stomach ulcers, and can lead to gastric cancer....
SEP 26, 2018
Videos
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
Loading Comments...